Toward aggregation-resistant antibodies by design

Trends in Biotechnology

Volumn 31, Issue 11, 2013, Pages 612-620

  Lee, Christine C ^a   Perchiacca, Joseph M ^a   Tessier, Peter M ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Antibody engineering; Bispecific; Complementarity determining region (CDR); Fab; Fv; IgG; Monoclonal antibody; ScFv; Solubility; VH; VL; Variable domain

Indexed keywords

ANTIBODY ENGINEERING; BISPECIFIC; COMPLEMENTARITY-DETERMINING REGIONS; FAB; FV; IGG; SCFV; VARIABLE DOMAIN;

BINDING ENERGY; MONOCLONAL ANTIBODIES;

SOLUBILITY;

MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB;

ALGORITHM; AMINO TERMINAL SEQUENCE; ANTIBODY ENGINEERING; ANTIGEN ANTIBODY COMPLEX; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DISULFIDE BOND; DRUG DESIGN; DRUG SOLUBILITY; DRUG STRUCTURE; HYDROPHILICITY; HYDROPHOBICITY; MOLECULAR SIZE; MUTATION; PRIORITY JOURNAL; REVIEW;

ANTIBODY ENGINEERING; BISPECIFIC; COMPLEMENTARITY-DETERMINING REGION (CDR); FAB; FV; IGG; MONOCLONAL ANTIBODY; SCFV; SOLUBILITY; V(H); V(L); VARIABLE DOMAIN;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; HUMANS; PROTEIN DENATURATION; PROTEIN ENGINEERING; PROTEIN STABILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84886100430     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.07.002     Document Type: Review

References (85)

1. McCafferty J., et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348:552-554.
2. Winter G., et al. Making antibodies by phage display technology. Annu. Rev. Immunol. 1994, 12:433-455.
3. Sidhu S.S. Phage display in pharmaceutical biotechnology. Curr. Opin. Biotechnol. 2000, 11:610-616.
4. Bradbury A.R., et al. Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotechnol. 2011, 29:245-254.
5. Boder E.T., Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 1997, 15:553-557.
6. Pirofski L., et al. Current state of the hybridoma technology. J. Clin. Immunol. 1990, 10:5-14.
7. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
8. Reichert J.M. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 2008, 9:423-430.
9. Reichert J.M., et al. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 2005, 23:1073-1078.
10. Perchiacca J.M., Tessier P.M. Engineering aggregation-resistant antibodies. Annu. Rev. Chem. Biomol. Eng. 2012, 3:263-286.
11. Lowe D., et al. Aggregation, stability, and formulation of human antibody therapeutics. Adv. Protein Chem. Struct. Biol. 2011, 84:41-61.
12. Shire S.J. Formulation and manufacturability of biologics. Curr. Opin. Biotechnol. 2009, 20:708-714.
13. Singh S.K. Impact of product-related factors on immunogenicity of biotherapeutics. J. Pharm. Sci. 2011, 100:354-387.
14. Jefferis R. Aggregation, immune complexes and immunogenicity. mAbs 2011, 3:503-504.
15. Hermeling S., et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 2004, 21:897-903.
16. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
17. Holt L.J., et al. Domain antibodies: proteins for therapy. Trends Biotechnol. 2003, 21:484-490.
18. Ravetch J.V., Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 2001, 19:275-290.
19. Wright A., et al. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J. 1991, 10:2717-2723.
20. Valliere-Douglass J.F., et al. Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies. J. Biol. Chem. 2009, 284:32493-32506.
21. Spiegelberg H.L., et al. Localization of the carbohydrate within the variable region of light and heavy chains of human gamma g myeloma proteins. Biochemistry 1970, 9:4217-4223.
22. Jespers L., et al. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat. Biotechnol. 2004, 22:1161-1165.
23. Jespers L., et al. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J. Mol. Biol. 2004, 337:893-903.
24. Dudgeon K., et al. Sequence determinants of protein aggregation in human VH domains. Protein Eng. Des. Sel. 2009, 22:217-220.
25. Linding R., et al. A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins. J. Mol. Biol. 2004, 342:345-353.
26. Conchillo-Sole O., et al. AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. BMC Bioinformatics 2007, 8:65.
27. Trovato A., et al. The PASTA server for protein aggregation prediction. Protein Eng. Des. Sel. 2007, 20:521-523.
28. Goldschmidt L., et al. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc. Natl. Acad. Sci. U.S.A. 2011, 107:3487-3492.
29. Maurer-Stroh S., et al. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat. Methods 2010, 7:237-242.
30. Wang X., et al. Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Pharm. Res. 2010, 27:1512-1529.
31. Wang X., et al. Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies. mAbs 2009, 1:254-267.
32. Buck P.M., et al. Computational methods to predict therapeutic protein aggregation. Methods Mol. Biol. 2012, 899:425-451.
33. Perchiacca J.M., et al. Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. Proteins 2011, 79:2637-2647.
34. Perchiacca J.M., et al. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng. Des. Sel. 2012, 25:591-602.
35. Perchiacca J.M., et al. Structure-based design of conformation- and sequence-specific antibodies against amyloid beta. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:84-89.
36. Ladiwala A.R., et al. Rational design of potent domain antibody inhibitors of amyloid fibril assembly. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:19965-19970.
37. Dudgeon K., et al. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10879-10884.
38. Wu S.J., et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng. Des. Sel. 2010, 23:643-651.
39. Bethea D., et al. Mechanisms of self-association of a human monoclonal antibody CNTO607. Protein Eng. Des. Sel. 2012, 25:531-537.
40. Pepinsky R.B., et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci. 2010, 19:954-966.
41. Chennamsetty N., et al. Design of therapeutic proteins with enhanced stability. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:11937-11942.
42. Schaefer J.V., Pluckthun A. Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris and mammalian cell expression. J. Mol. Biol. 2012, 417:309-335.
43. Kayser V., et al. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol. J. 2011, 6:38-44.
44. Zheng K., et al. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs 2011, 3:568-576.
45. Price J.L., et al. N-glycosylation of enhanced aromatic sequons to increase glycoprotein stability. Biopolymers 2012, 98:195-211.
46. Lauer T.M., et al. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J. Pharm. Sci. 2012, 101:102-115.
47. Voynov V., et al. Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation. PLoS ONE 2009, 4:e8425.
48. Chennamsetty N., et al. Aggregation-prone motifs in human immunoglobulin G. J. Mol. Biol. 2009, 391:404-413.
49. Wang X., et al. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: observations from molecular dynamics simulations. Proteins 2013, 81:443-460.
50. Buck P.M., et al. Insights into the potential aggregation liabilities of the b12 Fab fragment via elevated temperature molecular dynamics. Protein Eng. Des. Sel. 2013, 26:195-206.
51. Miklos A.E., et al. Structure-based design of supercharged, highly thermoresistant antibodies. Chem. Biol. 2012, 19:449-455.
52. Lawrence M.S., et al. Supercharging proteins can impart unusual resilience. J. Am. Chem. Soc. 2007, 129:10110-10112.
53. Das R., Baker D. Macromolecular modeling with rosetta. Annu. Rev. Biochem. 2008, 77:363-382.
54. Arbabi-Ghahroudi M., et al. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points. Protein Eng. Des. Sel. 2009, 22:59-66.
55. Tan P.H., et al. Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. Immunotechnology 1998, 4:107-114.
56. Barthelemy P.A., et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 2008, 283:3639-3654.
57. Davies J., Riechmann L. Antibody VH domains as small recognition units. Biotechnology 1995, 13:475-479.
58. Wirtz P., Steipe B. Intrabody construction and expression III: engineering hyperstable V(H) domains. Protein Sci. 1999, 8:2245-2250.
59. Riechmann L. Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain. J. Mol. Biol. 1996, 259:957-969.
60. Muyldermans S., et al. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 1994, 7:1129-1135.
61. Hamers-Casterman C., et al. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
62. Muyldermans S., et al. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem. Sci. 2001, 26:230-235.
63. Nguyen V.K., et al. Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 2000, 19:921-930.
64. Bond C.J., et al. Contributions of CDR3 to VHH domain stability and the design of monobody scaffolds for naive antibody libraries. J. Mol. Biol. 2003, 332:643-655.
65. Desmyter A., et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 1996, 3:803-811.
66. Spinelli S., et al. The crystal structure of a llama heavy chain variable domain. Nat. Struct. Biol. 1996, 3:752-757.
67. Kim D.Y., et al. Disulfide linkage engineering for improving biophysical properties of human VH domains. Protein Eng. Des. Sel. 2012, 25:581-589.
68. Buchanan A., et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. mAbs 2013, 5:255-262.
69. Hagihara Y., et al. Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region. J. Biol. Chem. 2007, 282:36489-36495.
70. Chan P.H., et al. Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils. Biochemistry 2008, 47:11041-11054.
71. Saerens D., et al. Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J. Mol. Biol. 2008, 377:478-488.
72. Hussack G., et al. Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS ONE 2011, 6:e28218.
73. Hussack G., et al. Characterization of single-domain antibodies with an engineered disulfide bond. Methods Mol. Biol. 2012, 911:417-429.
74. Reiter Y., et al. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng. 1994, 7:697-704.
75. Brinkmann U., et al. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:7538-7542.
76. Young N.M., et al. Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. FEBS Lett. 1995, 377:135-139.
77. Zhao J.X., et al. Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity. Int. J. Mol. Sci. 2010, 12:1-11.
78. Michaelson J.S., et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. mAbs 2009, 1:128-141.
79. Worn A., Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 2001, 305:989-1010.
80. Miller B.R., et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng. Des. Sel. 2010, 23:549-557.
81. Wang N., et al. Conserved amino acid networks involved in antibody variable domain interactions. Proteins 2009, 76:99-114.
82. Honegger A., et al. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng. Des. Sel. 2009, 22:121-134.
83. Ewert S., et al. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. Biochemistry 2003, 42:1517-1528.
84. Monsellier E., Bedouelle H. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms. J. Mol. Biol. 2006, 362:580-593.
85. Kuroda D., et al. Computer-aided antibody design. Protein Eng. Des. Sel. 2012, 25:507-521.